OFATUMUMAB (Kesimpta ®)

Clinical Indication

For treating relapsing multiple sclerosis

Comments

In line with NICE TA699

Implementation date 19th August 2021

Date of classification

July 2021

Review date

July 2021

Red

Drugs which should be prescribed only by hospital specialists (clinical review by specialist as appropriate and annually as a minimum).